Perseus Proteomics (TSE:4882) ROCE % : -54.65% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Perseus Proteomics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Perseus Proteomics's annualized ROCE % for the quarter that ended in Dec. 2023 was -54.65%.

Perseus Proteomics ROCE % Historical Data

The historical data trend for Perseus Proteomics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Perseus Proteomics ROCE % Chart

Perseus Proteomics Annual Data

Trend

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

ROCE %

Get a 7-Day Free Trial

-10.28

-89.59

-52.47

-22.30

-24.89

Perseus Proteomics Quarterly Data
	Mar18	Mar19	Dec19	Mar20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial												-24.67	-34.74	-41.48	-42.34	-54.65

Perseus Proteomics ROCE % Calculation

Perseus Proteomics's annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	-697.77	/	( ( (3300.53 - 148.375)	+	(2566.65 - 111.117) )	/ 2 )
	=	-697.77	/	( (3152.155	+	2455.533)	/ 2 )
	=	-697.77	/	2803.844
	=	-24.89 %

Perseus Proteomics's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-980.98	/	( ( (1989.786 - 96.856)	+	(1796.664 - 99.615) )	/ 2 )
	=	-980.98	/	( ( 1892.93	+	1697.049 )	/ 2 )
	=	-980.98	/	1794.9895
	=	-54.65 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Perseus Proteomics (TSE:4882) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Perseus Proteomics ROCE % Related Terms

Thank you for viewing the detailed overview of Perseus Proteomics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Perseus Proteomics (TSE:4882) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Perseus Proteomics Inc (TSE:4882) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

4-7-6, Komaba, Tokyo Park Building, Meguro-ku, Tokyo, JPN, 153-0041

Website

https://www.ppmx.com

Perseus Proteomics Inc is engaged in the research and development, manufacture, and sales of pharmaceuticals. It provides antibody based therapeutics and diagnostics drugs to cure against cancer and other diseases.

Perseus Proteomics (TSE:4882) Headlines

No Headlines